Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study (THYGEMOX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02472080|
Recruitment Status : Terminated (inefficiency)
First Posted : June 15, 2015
Last Update Posted : March 18, 2019
Radioiodine refractory differentiated thyroid cancer is a rare tumor and therapeutic options are limited in this setting. Molecular targeted therapies have recently been developed for progressive disease and demonstrated clinical activity, especially with anti-angiogenic agents.
For patients with contra-indication to these agents or in case of progression or toxicity during treatment, chemotherapy is usually proposed but this strategy has not been validated by prospective data.
The investigators propose to conduct an open single arm phase 2 study to evaluate response rate according to RECIST 1.1 with GEMOX regimen (gemcitabine - oxaliplatin combination) for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.
|Condition or disease||Intervention/treatment||Phase|
|Thyroid Cancer||Drug: gemcitabine -oxaliplatine combination||Phase 2|
The aim is to study efficacy of chemotherapy with gemcitabine - oxaliplatin combination for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.
For refractory thyroid cancer patients, in case of contra-indication to molecular targeted therapies or in case of progression or toxicity during treatment, alternative treatments are urgently needed.
Our study could precise if cytotoxic agents should remain a treatment option for refractory thyroid cancer after molecular targeted therapies or in case of contra-indication.
Numerous clinical trials are proposed to evaluate various molecular targeted therapies for refractory thyroid cancer, either conducted by institutional or industrial promoters. In contrast, chemotherapy trials are lacking. As generics are actually available for gemcitabine and oxaliplatin, no industrial support can be expected and prospective evaluation a chemotherapy regimen need to be conducted by an institutional promoter ("Assistance Publique - Hôpitaux de Paris"), supported by many French expert teams through the rare tumor network ""TUTHYREF"".
GEMOX regimen will be administrated intravenously every two weeks in ambulatory setting.
The objective of this study is to analyse the efficacy of chemotherapy with gemcitabine - oxaliplatin combination for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.
The primary end point is overall response rate (complete + partial response - CR+PR), according to RECIST 1.1, assessed by local investigator at 4 months.
30 patients will be included in a two steps design (Fleming design). A response rate lower than 15% define the inefficacy level. Minimal efficacy should be 35% response rate.
First step: inclusion of 15 patients. If 2 or less responses are observed: end of study for inefficacy If 6 or more responses are observed: efficacy endpoint has been reached If 3 to 5 responses are observed, additional inclusions are needed. Second step: inclusion of 15 additional patients. Nine responses are expected to define a positive study. Details are presented in statistical section.
The secondary end points are:
- Safety report according to NCI CTCAE v 4.0 grading scale
- Early metabolic response rate on 18F-FDG-PET/CT at 2 months
- Disease control rate (DCR = CR + PR + SD) ≥ 6 months
- Duration of response
- Time to progression
- Progression free survival
- Overall survival.
- Evolution of quality of life according to Fact-G and EQ-5D "
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients|
|Actual Study Start Date :||April 7, 2016|
|Actual Primary Completion Date :||April 1, 2018|
|Actual Study Completion Date :||January 15, 2019|
|Experimental: gemcitabine -oxaliplatine combination||
Drug: gemcitabine -oxaliplatine combination
gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
- overall response rate [ Time Frame: 4 months ]overall response rate measured (complete and partial responses) by CT-scan according to RECIST criteria v1.1
- number of adverse events and serious adverse events (AE) according to CTCAE v4.03 [ Time Frame: up to 12 month ]recording number of adverse events and serious adverse events (AE) according to CTCAE v4.03, during chemotherapy and follow up.
- Early metabolic response rate on 18F-FDG-TEP/CT [ Time Frame: 2 months ]semi-quantitative PET Response Criteria in Solid Tumors PERCIST1.0 "modified" using SUVmax and body-weight. Central reviewing of FDG-PET data by two readers at the end of the study will be done.
- Disease control rate [ Time Frame: 4 months ]Disease control rate (DCR) is defined as the percentage of patients who have achieved complete response (CR), partial response (PR) or stable disease (SD).
- Time to progression [ Time Frame: up to 36 months ]Time from documentation of tumor response to disease progression or date of death from any cause
- Progression free survival [ Time Frame: up to 36 months ]Time from documentation of tumor response to disease progression or date of death from any cause
- Overall survival [ Time Frame: up to 36 months ]Delay between inclusion and death from any cause
- Quality of life [ Time Frame: at day 1(week 1, i.e first cycle) and repeated every 28 days (i.e at W5, W9, W13, W17) during chemotherapy and every 3 months until 12 months ]evolution of quality of life will be assessed by the scores at the FACT-G and EQ-5D surveys (French version)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02472080
|Groupe Hospitalier Pitié Salpetriere|
|Paris, France, 75013|
|Principal Investigator:||Laurence Leenhardt||Assistance Publique - Hôpitaux de Paris|